SIRT2 inhibitor AGK2 evokes the upregulation of the level of ACLY acetylation and the downregulation of ACLY protein level, further resulting in the suppression of ESCC progression (Figure 10). The gene discussed is ACLY; the disease is esophageal squamous cell carcinoma.